RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy
Background : In the COOPERATE trial , the combination treatment of the angiotensin-II receptor blocker losartan and the angiotensin-converting-enzyme inhibitor tr and olapril significantly retarded progression of non-diabetic kidney disease compared with each monotherapy . The benefit could be greatly attributable to the potent reduction of proteinuria , because the three treatment groups showed the same reductions of office blood pressure ( OBP ) . Ambulatory blood pressure ( ABP ) is reported to be better than OBP in predicting progression of kidney disease . Methods : Ninety-two patients enrolled in the COOPERATE trial underwent 24-hour ABP monitoring  at r and omization and at month 6 , year 1 , year 2 and year 3 on r and omized treatment . Results : Both OBP and ABP were similarly reduced among the three groups at all measurement points ( p = NS ) and throughout the whole study period ( p = NS ) . No significant correlation between the change in 24-hour ABP and the change in proteinuria was seen ( p = NS ) . A Cox-multivariable analysis showed that covariates affecting the renal outcomes ( a doubling serum-Cr level and /or end-stage renal failure ) were the change in proteinuria ( hazard ratio 0.49 , 95 % CI 0.34–0.78 , p = 0.01 ) and treatments ( 0.58 , 0.45–0.99 , 0.03 ) , but not 24-hour ABP ( 0.98 , 0.89–2.01 , 0.17 ) . Conclusion : The better renoprotective effect of the combination treatment is attributed to BP-independent mechanisms by more complete renin-angiotensin system blockade
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .